DeFord John A 4

What Happened

• John A. DeFord, a director of Globus Medical (GMED), received a grant of 15,000 derivative securities (stock options) on January 21, 2026. The Form 4 reports an acquisition at $0.00 (no cash paid at grant).
• The filing classifies the transaction as an award/grant (code A). The reported acquisition amount is $0.00; the strike/exercise price and other option terms are not specified in this summary.

Key Details

• Transaction date: 2026-01-21; Form 4 filed: 2026-01-23 (appears timely within the typical 2-business-day window).
• Quantity: 15,000 options granted; reported price: $0.00 (grant reported as a derivative acquisition).
• Vesting: Footnote F1 states these options will vest on January 1, 2027.
• Shares owned after transaction: not specified in the information provided.
• No 10b5-1 plan, tax-withholding, or cashless-exercise details are included in the provided filing.

Context

• This was an option award (a derivative grant), not an open-market purchase or sale. Options give the holder the right to buy shares in the future if and when vested/exercised; they do not represent immediate share sales. As reported, the award vests on Jan 1, 2027, after which DeFord may be able to exercise according to the option terms (not detailed here).